Stocks and Investing Stocks and Investing
Tue, August 2, 2022

Nathan Rich Maintained (TEVA) at Hold with Increased Target to $10 on, Aug 2nd, 2022


Published on 2024-10-27 22:21:39 - WOPRAI, Nathan Rich
  Print publication without navigation


Nathan Rich of Goldman Sachs, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Increased Target from $9 to $10 on, Aug 2nd, 2022.

Nathan has made no other calls on TEVA in the last 4 months.



There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Nathan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Ashwani Verma of "UBS" Initiated at Hold and Held Target at $10 on, Tuesday, June 14th, 2022
  • Jason Gerberry of "B of A Securities" Upgraded from Sell to Hold and Held Target at $9 on, Tuesday, May 17th, 2022


These are the ratings of the 2 analyists that currently disagree with Nathan


  • David Amsellem of "Piper Sandler" Downgraded from Hold to Sell and Decreased Target to $7 on, Wednesday, May 4th, 2022
  • Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
Contributing Sources